NCT00632736View on ClinicalTrials.gov

An Open-label Continuation Study Evaluating the Long-term Safety of Extended Release Ropinirole XL (Formerly CR) in Parkinson''s Disease

PHASE3CompletedINTERVENTIONAL
Enrollment

419

Participants

Timeline

Start Date

February 29, 2004

Primary Completion Date

March 31, 2010

Study Completion Date

March 31, 2010

Conditions
Parkinson DiseaseParkinson's Disease
Interventions
DRUG

Ropinirole XL (formerly CR)

Trial Locations (75)

1083

GSK Investigational Site, Budapest

1096

GSK Investigational Site, Budapest

1135

GSK Investigational Site, Budapest

1145

GSK Investigational Site, Budapest

1200

GSK Investigational Site, Brussels

1204

GSK Investigational Site, Budapest

2660

GSK Investigational Site, Hoboken

3000

GSK Investigational Site, Leuven

3500

GSK Investigational Site, Hasselt

3526

GSK Investigational Site, Miskolc

3529

GSK Investigational Site, Miskolc

7623

GSK Investigational Site, Pécs

8800

GSK Investigational Site, Roeselare

12205

GSK Investigational Site, Albany

13616

GSK Investigational Site, Aix-en-Provence

19013

GSK Investigational Site, Upland

19107

GSK Investigational Site, Philadelphia

27705

GSK Investigational Site, Durham

30342

GSK Investigational Site, Atlanta

30912

GSK Investigational Site, Augusta

32127

GSK Investigational Site, Port Orange

32405

GSK Investigational Site, Panama City

33486

GSK Investigational Site, Boca Raton

33606

GSK Investigational Site, Tampa

33701

GSK Investigational Site, St. Petersburg

35294

GSK Investigational Site, Birmingham

36057

GSK Investigational Site, Vicenza

48025

GSK Investigational Site, Bingham Farms

48034

GSK Investigational Site, Southfield

49684

GSK Investigational Site, Traverse City

53233

GSK Investigational Site, Milwaukee

55043

GSK Investigational Site, Lido Di Camaiore (LU)

58100

GSK Investigational Site, Grosseto

59037

GSK Investigational Site, Lille

60025

GSK Investigational Site, Glenview

65100

GSK Investigational Site, Pescara

66160

GSK Investigational Site, Kansas City

68250

GSK Investigational Site, Rouffach

76301

GSK Investigational Site, Wichita Falls

78229

GSK Investigational Site, San Antonio

80110

GSK Investigational Site, Englewood

86077

GSK Investigational Site, Pozzilli (IS)

92708

GSK Investigational Site, Fountain Valley

94109

GSK Investigational Site, San Francisco

02215

GSK Investigational Site, Boston

43614-5809

GSK Investigational Site, Toledo

656 91

GSK Investigational Site, Brno

500 05

GSK Investigational Site, Hradec Králové

703 52

GSK Investigational Site, Ostrava

710 00

GSK Investigational Site, Ostrava

535 03

GSK Investigational Site, Pardubice

304 60

GSK Investigational Site, Plzen - Lochotin

100 34

GSK Investigational Site, Prague

120 00

GSK Investigational Site, Prague

H-4012

GSK Investigational Site, Debrecen

Unknown

GSK Investigational Site, Vasvari Pal Street 2, H=9023 Gyor

15-276

GSK Investigational Site, Bialystok

66-212

GSK Investigational Site, Cibórz

80-211

GSK Investigational Site, Gdansk

80-299

GSK Investigational Site, Gdansk

40-752

GSK Investigational Site, Katowice

31-530

GSK Investigational Site, Krakow

64-100

GSK Investigational Site, Leszno

20-718

GSK Investigational Site, Lublin

20-954

GSK Investigational Site, Lublin

61-285

GSK Investigational Site, Poznan

87-100

GSK Investigational Site, Torun

01-337

GSK Investigational Site, Warsaw

02-097

GSK Investigational Site, Warsaw

08025

GSK Investigational Site, Barcelona

G51 4TF

GSK Investigational Site, Glasgow

FY3 8BP

GSK Investigational Site, Blackpool

NE4 6BE

GSK Investigational Site, Newcastle upon Tyne

KT16 0QA

GSK Investigational Site, Chertsey

SA6 6NL

GSK Investigational Site, Swansea

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT00632736 - An Open-label Continuation Study Evaluating the Long-term Safety of Extended Release Ropinirole XL (Formerly CR) in Parkinson''s Disease | Biotech Hunter | Biotech Hunter